Zhejiang East Asia Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
Zhejiang East Asia Pharmaceutical's earnings have been declining at an average annual rate of -5.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 23.8% per year. Zhejiang East Asia Pharmaceutical's return on equity is 6.1%, and it has net margins of 9.1%.
Key information
-5.6%
Earnings growth rate
-16.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 23.8% |
| Return on equity | 6.1% |
| Net Margin | 9.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Zhejiang East Asia Pharmaceutical's (SHSE:605177) Solid Profits Have Weak Fundamentals
May 06
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Apr 23Take Care Before Diving Into The Deep End On Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE:605177)
Feb 28Revenue & Expenses BreakdownBeta
How Zhejiang East Asia Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,339 | 122 | 158 | 87 |
| 31 Dec 23 | 1,356 | 121 | 150 | 82 |
| 30 Sep 23 | 1,330 | 129 | 136 | 68 |
| 31 Mar 23 | 1,294 | 105 | 133 | 51 |
| 31 Dec 22 | 1,180 | 104 | 124 | 45 |
| 30 Sep 22 | 1,094 | 76 | 131 | 41 |
| 30 Jun 22 | 902 | 52 | 124 | 38 |
| 31 Mar 22 | 778 | 66 | 118 | 36 |
| 31 Dec 21 | 712 | 68 | 115 | 37 |
| 30 Sep 21 | 677 | 60 | 118 | 35 |
| 30 Jun 21 | 720 | 87 | 115 | 37 |
| 31 Mar 21 | 926 | 132 | 123 | 41 |
| 31 Dec 20 | 882 | 114 | 128 | 38 |
| 30 Sep 20 | 941 | 146 | 125 | 39 |
| 31 Dec 19 | 988 | 168 | 110 | 37 |
| 31 Dec 18 | 857 | 109 | 94 | 33 |
| 31 Dec 17 | 729 | 56 | 90 | 31 |
| 31 Dec 16 | 684 | 67 | 82 | 27 |
Quality Earnings: 605177 has a high level of non-cash earnings.
Growing Profit Margin: 605177's current net profit margins (9.1%) are higher than last year (8.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605177's earnings have declined by 5.6% per year over the past 5 years.
Accelerating Growth: 605177's earnings growth over the past year (16.1%) exceeds its 5-year average (-5.6% per year).
Earnings vs Industry: 605177 earnings growth over the past year (16.1%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 605177's Return on Equity (6.1%) is considered low.